BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 9746768)

  • 21. A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for haematological malignancy.
    Atkinson K; Biggs J; Concannon A; Dodds A; Young S; Wilson F; Ashby M; Downs K
    Aust N Z J Med; 1991 Dec; 21(6):850-6. PubMed ID: 1818544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation.
    Tseng LH; Lin MT; Hansen JA; Gooley T; Pei J; Smith AG; Martin EG; Petersdorf EW; Martin PJ
    Blood; 1999 Oct; 94(8):2911-4. PubMed ID: 10515896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
    Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
    Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells.
    Inamoto Y; Flowers ME; Appelbaum FR; Carpenter PA; Deeg HJ; Furlong T; Kiem HP; Mielcarek M; Nash RA; Storb RF; Witherspoon RP; Storer BE; Martin PJ
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1088-92. PubMed ID: 21421070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation.
    Wingard JR; Nash RA; Przepiorka D; Klein JL; Weisdorf DJ; Fay JW; Zhu J; Maher RM; Fitzsimmons WE; Ratanatharathorn V
    Biol Blood Marrow Transplant; 1998; 4(3):157-63. PubMed ID: 9923414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO).
    Bacigalupo A; Lamparelli T; Bruzzi P; Guidi S; Alessandrino PE; di Bartolomeo P; Oneto R; Bruno B; Barbanti M; Sacchi N; Van Lint MT; Bosi A
    Blood; 2001 Nov; 98(10):2942-7. PubMed ID: 11698275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial.
    Wagner JE; Thompson JS; Carter SL; Kernan NA;
    Lancet; 2005 Aug 27-Sep 2; 366(9487):733-41. PubMed ID: 16125590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC
    Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis.
    Yagasaki H; Kojima S; Yabe H; Kato K; Kigasawa H; Sakamaki H; Tsuchida M; Kato S; Kawase T; Muramatsu H; Morishima Y; Kodera Y
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1603-8. PubMed ID: 19896085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation.
    Przepiorka D; Ippoliti C; Khouri I; Woo M; Mehra R; Le Bherz D; Giralt S; Gajewski J; Fischer H; Fritsche H; Deisseroth AB; Cleary K; Champlin R; Besien K; Andersson B; Maher R; Fitzsimmons W
    Blood; 1996 Dec; 88(11):4383-9. PubMed ID: 8943876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial.
    Locatelli F; Zecca M; Rondelli R; Bonetti F; Dini G; Prete A; Messina C; Uderzo C; Ripaldi M; Porta F; Giorgiani G; Giraldi E; Pession A
    Blood; 2000 Mar; 95(5):1572-9. PubMed ID: 10688810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP
    Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial.
    Locatelli F; Bruno B; Zecca M; Van-Lint MT; McCann S; Arcese W; Dallorso S; Di Bartolomeo P; Fagioli F; Locasciulli A; Lawler M; Bacigalupo A
    Blood; 2000 Sep; 96(5):1690-7. PubMed ID: 10961865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K; Downs K
    Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate.
    Nash RA; Pepe MS; Storb R; Longton G; Pettinger M; Anasetti C; Appelbaum FR; Bowden RA; Deeg HJ; Doney K
    Blood; 1992 Oct; 80(7):1838-45. PubMed ID: 1391947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan.
    Yanada M; Emi N; Naoe T; Sakamaki H; Takahashi S; Hirabayashi N; Hiraoka A; Kanda Y; Tanosaki R; Okamoto S; Iwato K; Atsuta Y; Hamajima N; Tanimoto M; Kato S
    Bone Marrow Transplant; 2004 Aug; 34(4):331-7. PubMed ID: 15220958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors].
    Hamazaki T; Yagi K; Inoue M; Sakata N; Okamura T; Yasui M; Sasabe M; Kishimoto T; Inoue A; Kawa K
    Rinsho Ketsueki; 2000 May; 41(5):430-6. PubMed ID: 10879106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial.
    Chao NJ; Snyder DS; Jain M; Wong RM; Niland JC; Negrin RS; Long GD; Hu WW; Stockerl-Goldstein KE; Johnston LJ; Amylon MD; Tierney DK; O'Donnell MR; Nademanee AP; Parker P; Stein A; Molina A; Fung H; Kashyap A; Kohler S; Spielberger R; Krishnan A; Rodriguez R; Forman SJ; Bluzme KG
    Biol Blood Marrow Transplant; 2000; 6(3):254-61. PubMed ID: 10871150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.